Search Results
Search for other papers by Lamis Yehia in
Google Scholar
PubMed
Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Germline High Risk Cancer Focus Group, CASE Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
Search for other papers by Charis Eng in
Google Scholar
PubMed
ASD. Over the last two decades, significant progress has been made in understanding the molecular and genetic mechanisms related to PTEN and associated pathway dysfunction. The existence of a known gene allows for the establishment of a molecular
Search for other papers by Pablo Valderrabano in
Google Scholar
PubMed
Search for other papers by Laila Khazai in
Google Scholar
PubMed
Search for other papers by Marino E Leon in
Google Scholar
PubMed
Search for other papers by Zachary J Thompson in
Google Scholar
PubMed
Search for other papers by Zhenjun Ma in
Google Scholar
PubMed
Search for other papers by Christine H Chung in
Google Scholar
PubMed
Search for other papers by Julie E Hallanger-Johnson in
Google Scholar
PubMed
Search for other papers by Kristen J Otto in
Google Scholar
PubMed
Search for other papers by Kara D Rogers in
Google Scholar
PubMed
Search for other papers by Barbara A Centeno in
Google Scholar
PubMed
Search for other papers by Bryan McIver in
Google Scholar
PubMed
ThyroSeq v2 claims high positive (PPV) and negative (NPV) predictive values in a wide range of pretest risks of malignancy in indeterminate thyroid nodules (ITNs) (categories B-III and B-IV of the Bethesda system). We evaluated ThyroSeq v2 performance in a cohort of patients with ITNs seen at our Academic Cancer Center from September 2014 to April 2016, in light of the new diagnostic criteria for non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Our study included 182 patients (76% female) with 190 ITNs consecutively tested with ThyroSeq v2. Patient treatment followed our institutional thyroid nodule clinical pathway. Histologies of nodules with follicular variant papillary thyroid carcinoma or NIFTP diagnoses were reviewed, with reviewers blinded to molecular results. ThyroSeq v2 performance was calculated in nodules with histological confirmation. We identified a mutation in 24% (n = 45) of the nodules. Mutations in RAS were the most prevalent (n = 21), but the positive predictive value of this mutation was much lower (31%) than that in prior reports. In 102 resected ITNs, ThyroSeq v2 performance was as follows: sensitivity 70% (46–88), specificity 77% (66–85), PPV 42% (25–61) and NPV 91% (82–97). The performance in B-IV nodules was significantly better than that in B-III nodules (area under the curve 0.84 vs 0.57, respectively; P = 0.03), where it was uninformative. Further studies evaluating ThyroSeq v2 performance are needed, particularly in B-III.
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Marina Muzza in
Google Scholar
PubMed
Search for other papers by Gabriele Pogliaghi in
Google Scholar
PubMed
Search for other papers by Sonia Palazzo in
Google Scholar
PubMed
Search for other papers by Guia Vannucchi in
Google Scholar
PubMed
Search for other papers by Leonardo Vicentini in
Google Scholar
PubMed
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Giacomo Gazzano in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Cytology is the gold standard method for the differential diagnosis of thyroid nodules, though 25–30% of them are classified as indeterminate. We aimed to set up a ‘thyroid risk score’ (TRS) to increase the diagnostic accuracy in these cases. We prospectively tested 135 indeterminate thyroid nodules. The pre-surgical TRS derived from the sum of the scores assigned at cytology, EU-TIRADS classification, nodule measurement, and molecular characterization, which was done by our PTC-MA assay, a customized array able to cost-effectively evaluate 24 different genetic alterations including point mutations and gene fusions. The risk of malignancy (ROM) increased paralleling the score: in the category >4 and ≤ 6 (low suspicion), >6 ≤ 8 (intermediate suspicion), and >8 (high suspicion); ROM was 10, 47 and 100%, respectively. ROC curves selected the score >6.5 as the best threshold to differentiate between malignant and benign nodules (P < 0.001). The TRS > 6.5 had a better performance than the single parameters evaluated separately, with an accuracy of 77 and 82% upon inclusion of noninvasive follicular thyroid neoplasm with papillary-like nuclear features among malignant or benign cases, respectively. In conclusion, for the first time, we generated a score combining a cost-effective molecular assay with already validated tools, harboring different specificities and sensitivities, for the differential diagnosis of indeterminate nodules. The combination of different parameters reduced the number of false negatives inherent to each classification system. The TRS > 6.5 was highly suggestive for malignancy and retained a high accuracy in the identification of patients to be submitted to surgery.
Search for other papers by Sergio Vargas-Salas in
Google Scholar
PubMed
Search for other papers by José R Martínez in
Google Scholar
PubMed
Search for other papers by Soledad Urra in
Google Scholar
PubMed
Search for other papers by José Miguel Domínguez in
Google Scholar
PubMed
Search for other papers by Natalia Mena in
Google Scholar
PubMed
Search for other papers by Thomas Uslar in
Google Scholar
PubMed
Search for other papers by Marcela Lagos in
Google Scholar
PubMed
Search for other papers by Marcela Henríquez in
Google Scholar
PubMed
Search for other papers by Hernán E González in
Google Scholar
PubMed
right test’ should be considered to perform an appropriate molecular diagnosis for ITC. Therefore, a comprehensive analysis of the available evidence supporting different tests will provide clinicians with a better understanding of tests performance and
Section of Preventive Medicine, Department of Endocrinology of the University of Medicine and Pharmacy ‘Victor Babes’, Private Praxis for Endocrinology, Endocrine Section, Endocrine Division, Institutos de Histología, Molecular Medicine Research Group, Hereditary Endocrine Cancer Group, Endocrinology Unit, Centro de Investigaciones Endocrinológicas, Department of Endocrinology, Department of Molecular Endocrinology of the Institute of Endocrinology, Department of Hypertension, Genomic Medicine Institute, Department of Nephrology, University of Freiburg Medical Centre, Freiburg im Breisgau, Germany
Search for other papers by Ioana N Milos in
Google Scholar
PubMed
Search for other papers by Karin Frank-Raue in
Google Scholar
PubMed
Search for other papers by Nelson Wohllk in
Google Scholar
PubMed
Search for other papers by Ana Luiza Maia in
Google Scholar
PubMed
Search for other papers by Eduardo Pusiol in
Google Scholar
PubMed
Search for other papers by Attila Patocs in
Google Scholar
PubMed
Search for other papers by Mercedes Robledo in
Google Scholar
PubMed
Search for other papers by Josefina Biarnes in
Google Scholar
PubMed
Search for other papers by Marta Barontini in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Jan Willem de Groot in
Google Scholar
PubMed
Search for other papers by Sarka Dvorakova in
Google Scholar
PubMed
Search for other papers by Mariola Peczkowska in
Google Scholar
PubMed
Search for other papers by Lisa A Rybicki in
Google Scholar
PubMed
Search for other papers by Maren Sullivan in
Google Scholar
PubMed
Search for other papers by Friedhelm Raue in
Google Scholar
PubMed
Search for other papers by Ioana Zosin in
Google Scholar
PubMed
Search for other papers by Charis Eng in
Google Scholar
PubMed
Search for other papers by Hartmut P H Neumann in
Google Scholar
PubMed
were found in the large majority of MEN 2 patients and a RET genotype–clinical phenotype found, this was the paradigm for the practice of clinical cancer genetics. Accurate molecular diagnosis and premorbid predictive testing became possible. Based on
Search for other papers by Charis Eng in
Google Scholar
PubMed
discovery of the RET protooncogene as the susceptibility gene of the relatively uncommon multiple endocrine neoplasia type 2 (MEN 2) led to an explosion of gene-based molecular diagnosis, predictive testing, and genotype-specific cancer risk assessment and
Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands
Search for other papers by Elizabeth J de Koster in
Google Scholar
PubMed
Search for other papers by Willem E Corver in
Google Scholar
PubMed
Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands
Biomedical Photonic Imaging Group, University of Twente, Enschede, the Netherlands
Search for other papers by Lioe-Fee de Geus-Oei in
Google Scholar
PubMed
Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, the Netherlands
Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy
Search for other papers by Wim J G Oyen in
Google Scholar
PubMed
Search for other papers by Dina Ruano in
Google Scholar
PubMed
Search for other papers by Abbey Schepers in
Google Scholar
PubMed
Search for other papers by Marieke Snel in
Google Scholar
PubMed
Search for other papers by Tom van Wezel in
Google Scholar
PubMed
Search for other papers by Dennis Vriens in
Google Scholar
PubMed
Search for other papers by Hans Morreau in
Google Scholar
PubMed
–LOH analysis using the GWLOH panel were interpreted as described in the flowchart in Fig. 2 , identifying the different types of CNA patterns and establishing a molecular diagnosis. First, the CNA type is identified as GH-type, reciprocal chromosomal imbalance
Search for other papers by William D Foulkes in
Google Scholar
PubMed
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
Department of Genetics and Genome Sciences and Germline High Risk Focus Group, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for other papers by Charis Eng in
Google Scholar
PubMed
multiple endocrine neoplasia type 2 (MEN 2), reviewed by Lois Mulligan ( Mulligan 2018 ), who was a co-discoverer of the first proto-oncogene cancer predisposition gene. This showed the way in molecular diagnosis, genotype–phenotype correlations and finally
Search for other papers by Paola Caria in
Google Scholar
PubMed
Search for other papers by Tinuccia Dettori in
Google Scholar
PubMed
Search for other papers by Daniela V Frau in
Google Scholar
PubMed
Search for other papers by Angela Borghero in
Google Scholar
PubMed
Search for other papers by Antonello Cappai in
Google Scholar
PubMed
Search for other papers by Alessia Riola in
Google Scholar
PubMed
Search for other papers by Maria L Lai in
Google Scholar
PubMed
Search for other papers by Francesco Boi in
Google Scholar
PubMed
Search for other papers by Piergiorgio Calò in
Google Scholar
PubMed
Search for other papers by Angelo Nicolosi in
Google Scholar
PubMed
Search for other papers by Stefano Mariotti in
Google Scholar
PubMed
Search for other papers by Roberta Vanni in
Google Scholar
PubMed
used as an adjunct to cytology. As these abnormalities rarely coexist in an individual PTC, testing for multiple alterations may improve the sensitivity of the molecular diagnosis. In this regard, a few gene classifiers are now commercially available
Search for other papers by A Raitila in
Google Scholar
PubMed
Search for other papers by M Georgitsi in
Google Scholar
PubMed
Search for other papers by A Karhu in
Google Scholar
PubMed
Search for other papers by K Tuppurainen in
Google Scholar
PubMed
Search for other papers by M J Mäkinen in
Google Scholar
PubMed
Search for other papers by K Birkenkamp-Demtröder in
Google Scholar
PubMed
Search for other papers by K Salmenkivi in
Google Scholar
PubMed
Search for other papers by T F Ørntoft in
Google Scholar
PubMed
Search for other papers by J Arola in
Google Scholar
PubMed
Search for other papers by V Launonen in
Google Scholar
PubMed
Search for other papers by P Vahteristo in
Google Scholar
PubMed
Search for other papers by L A Aaltonen in
Google Scholar
PubMed
. 2007b Molecular diagnosis of pituitary adenoma predisposition, caused by aryl hydrocarbon receptor interacting protein gene mutations. PNAS 104 4101 –4105. Iwata T , Yamada S, Mizusawa N, Golam HMD, Sano T & Yoshimoto K